AstriVax: committed to address real-world challenges in vaccinology

AstriVax is a privately held spin-off company from the KU Leuven, founded with a € 30 million seed round in 2022, based on vaccine technology developed at the university of Leuven. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.

We will use the raised capital to bring (1) the first thermostable yellow fever (YF) vaccine into a first-in-human Phase 1 trial, (2) to further advance two pipeline vaccine candidates towards clinical trials (e.g. vaccines on prevention of rabies and treatment of chronic hepatitis B (CHB)), (3) to clinically validate the platform technology on the basis of clinical data generated with YF, Rabies and CHB and (4) to fuel the preclinical pipeline with several prophylactic and therapeutic leads.

We target meetings with investors and possible partners in infectious disease and/or vaccine development.